Baricitinib
9 Inquiries
1187594-09-7
Pharmaceutical Grade
99%
Any China Port
1kg/as customer's requirment
2024-12-08
API,Intermediate
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionBasic Info
-
Product Name:
Baricitinib
Other Name:3-Azetidineacetonitrile,1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-;1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile;LY 3009104;Baricitinib;INCB 028050;INCB 28050;Olumiant;2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile;1231199-29-3;1374987-77-5
CAS No.:1187594-09-7
Molecular Formula:C16H17N7O2S
InChIKeys:InChIKey=XUZMWHLSFXCVMG-UHFFFAOYSA-N
Molecular Weight:371.41688
Exact Mass:371.42
EC Number:1592732-453-0
HScode:29350090
Categories:
Characteristics-
PSA:
129
XLogP3:-0.5
Density:1.56
Boiling Point:707.2
Flash Point:381.5±35.7 °C
Refractive Index:1.763
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Oral
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H302 Harmful if swallowed
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Distributor
-
Main Products:
API,Intermediate
-
Payment Terms:
TT against copy of documents,L/C
-
Average lead Time:
30
-
Total Annual Revenue:
Above $100 million
-
Total Employees:
201-300
About Echemi Pharmaceutical
Echemi’s philosophy is to seek for higher quality, to explore frontier area. The progress of human society, the extension of life expectancy, and the conquest of disease are all derived from the numerous businesses and individuals who have quietly dedicated themselves in the pharmaceutical industry. It’s the controlling of supply chain quality that ensures the efficacy. It’s the continuous exploration that promotes the development of the pharmaceutical industry and benefits more future generations. The pursuit of high quality requires all partners of Echemi Pharmaceutical to be screened, whether its certificate, qualification or scale. In the field of renewal, we will embrace all new changes and make more contributions to the development of pharmaceutical industry.
Advantage for Pharmaceutical
• Having been working in pharmaceutical field for more then 15 years, we have experienced regulatory team, quality control team, sourcing team, technical support team, and logistics team. And we are familiar with the regulatory requirements from different areas, can offer tailored service for our customers.
• We have hundreds of strategic partners for APIs, intermediates, and custom synthesis. All of our partners are ready to support our customers with documents, and be audited.
• We can offer custom synthesis for some new chemical structures and some materials which there are no reliable suppliers.
Product Category
We care for human and animal health and we are committed to creating a better social environment.
• Human API
• Intermediate
• Veterinary API
• Agrochemical
• Fine Chemical
• Custom Synthesis
-
-
Inquiry History9 Inquiries
Country Product Purchase Quantity Date Posted 
Poland
Baricitinib
500 MG Apr 28, 2026 
Bangladesh
Baricitinib
1000 KG May 6, 2024 
Pakistan
Baricitinib
1 KG Jun 4, 2025 
Thailand
baricitinib
10 G Sep 27, 2023 
India
Baricitinib
50 G Oct 17, 2025
India
Baricitinib
25.00 G Oct 14, 2025 
Bulgaria
Baricitinib
1 G Aug 18, 2025 
South Korea
Baricitinib
100 G Mar 27, 2025
Bangladesh
Butyl Acetate
1.00 KG Nov 11, 2025 Post an enquiry for this product